A common hormonal disorder affecting a significant number of women, previously known as Polycystic Ovary Syndrome (PCOS), has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change follows more than a decade of international consultation, spearheaded by endocrinologist Professor Helena Teede, director of Melbourne’s Monash Centre for Health Research and Implementation. The new nomenclature aims to more accurately represent the multifaceted nature of the condition, which impacts an estimated 170 million women worldwide.
In the UK, PCOS, now PMOS, affects approximately one in eight women. This makes it one of the most prevalent hormonal conditions among women of reproductive age. Symptoms can vary widely but often include irregular periods, excess androgen levels leading to symptoms like acne and hirsutism (excess body hair), and polycystic ovaries as seen on an ultrasound scan. However, it is important to note that not all women with PMOS have ovarian cysts, and not all women with ovarian cysts have PMOS.
The shift from 'Polycystic Ovary Syndrome' to 'Polyendocrine Metabolic Ovarian Syndrome' is significant because it moves the focus beyond just the ovaries. The term 'Polyendocrine' acknowledges the involvement of multiple endocrine glands and their hormones, while 'Metabolic' highlights the common metabolic disturbances associated with the condition, such as insulin resistance, which can increase the risk of type 2 diabetes and cardiovascular disease. This broader understanding is crucial for diagnosis and management.
For patients in the UK, this renaming primarily serves to enhance understanding of the condition's complexities. It reinforces that PMOS is not solely a gynaecological issue but a systemic disorder with endocrine and metabolic implications. While the name has changed, the diagnostic criteria and current treatment approaches, which often involve lifestyle modifications, medication to manage symptoms, and regular monitoring for associated health risks, remain consistent with current NHS guidelines. Patients should continue to seek advice from their GP for diagnosis and management.
The renaming of PCOS to PMOS reflects a growing scientific consensus on the breadth of the condition. It is hoped that this new terminology will lead to improved public awareness and a more comprehensive approach to patient care, encouraging healthcare professionals to consider all aspects of the disorder, not just reproductive symptoms. This could ultimately lead to better long-term health outcomes for women living with PMOS.
For anyone experiencing symptoms that might be related to PMOS, it is essential to consult a GP. They can provide an accurate diagnosis, discuss appropriate management strategies, and offer guidance on lifestyle changes and potential medical treatments. Further information and support can also be found through NHS 111 or reputable health organisations.
Source: Professor Helena Teede, Monash Centre for Health Research and Implementation